drugset / Trial / NCT04029922
Study of MT-5111 in HER2-positive Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) given as monotherapy in subjects with HER2-positive solid tumors
Timeline
- Start
- 2019-11-12
- Primary completion
- 2023-02-01
- Completion
- 2023-04-27
Outcome
Outcome not reported
Stopped: “Study Reprioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-5111 | Protein / enzyme biologic | — | Intravenous |